IL10 and renal cell carcinoma: Recombinant IL-10 protein exerted promising anti-tumor effects on solid tumors such as renal cell carcinoma and melanoma, but ideal therapeutic effects did not be observed on patients with MA-associated cancer types such as ovarian cancer and pancreatic cancer, and the agent’s direct efficacy on MA remains unknown, impeding its further clinical application [107].